menu
    • menu
    [{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Collaboration","leadProduct":"Cedazuridine","moa":"||Cytidine deaminase","graph1":"Oncology","graph2":"Undisclosed","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Oxaliplatin","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"BI 1701963","moa":"Pan-KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Adagrasib","moa":"KRAS G12C","graph1":"Oncology","graph2":"Phase III","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Mirati Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Mirati Therapeutics"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Durvalumab","moa":"||BRAF","graph1":"Oncology","graph2":"Phase II","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IGM-6268","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"WP1122","moa":"Glycolysis","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Moleculin Biotech","highestDevelopmentStatusID":"1","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Moleculin Biotech"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Refuge Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"RB-340","moa":"HER2","graph1":"Oncology","graph2":"Preclinical","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Refuge Biotechnologies","highestDevelopmentStatusID":"4","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Refuge Biotechnologies"},{"orgOrder":0,"company":"The University of Texas MD Anderson Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"WNT974","moa":"||Porcupine","graph1":"Oncology","graph2":"Phase I","graph3":"The University of Texas MD Anderson Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The University of Texas MD Anderson Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"The University of Texas MD Anderson Cancer Center \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by The University of Texas MD Anderson Cancer Center

    Menu

    The University of Texas MD Anderson Cancer Center

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adagrasib

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Mirati Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MD Anderson and Mirati Therapeutics Announce Kras Strategic Research AND Development Collaboration IN Solid Tu...

                            Details : The collaboration aims to expand the evaluation of Mirati's two investigational small molecule, adagrasib, a G12C inhibitor in clinical development, and MRTX1133 as monotherapy and in combination with other agents for two of the most frequent KRAS mutati...

                            Product Name : MRTX849

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 02, 2021

                            Lead Product(s) : Adagrasib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Mirati Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RB-340

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Refuge Biotechnologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            MD Anderson and Refuge Biotechnologies Collaborate to Advance Next-Generation Cell Therapies for Treatment of ...

                            Details : Collaboration supports co-development of RB-340, a HER-2 targeted CAR T- cell therapy with context-dependent and inducible down-regulation of PD-1, through Phase 2.

                            Product Name : RB-340

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 17, 2021

                            Lead Product(s) : RB-340

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Refuge Biotechnologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BI 1701963

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compou...

                            Details : The collaboration will explore lung cancer targeting KRAS and TRAILR2 molecules from Boehringer Ingelheim’s growing portfolio of cancer treatments and builds on its commitment to delivering first-in-class treatment options to people living with cancer.

                            Product Name : BI 1701963

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 14, 2021

                            Lead Product(s) : BI 1701963

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IGM-6268

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Preclinical Research Reveals that New IgM Antibodies Administered Intranasally to Fight Covid-19 More Potent t...

                            Details : Additionally, IGM-6268 was shown to be highly effective for prophylaxis and treatment in mouse models when administered intranasally.

                            Product Name : IGM-6268

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 06, 2021

                            Lead Product(s) : IGM-6268

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oxaliplatin,Fluorouracil,Irinotecan HCl Trihydrate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Aden...

                            Details : Neoadjuvant modified FOLFIRINOX (mFOLFIRINOX) improved overall survival relative to historical data in patients with borderline resectable adenocarcinoma of the pancreas; But, addition of hypofractionated radiation therapy did not improve OS compared to ...

                            Product Name : mFOLFIRINOX

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 21, 2021

                            Lead Product(s) : Oxaliplatin,Fluorouracil,Irinotecan HCl Trihydrate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Durvalumab,Trametinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Targeted Therapy Combination Effective for Patients with Advanced Cholangiocarcinoma and Braf Mutations

                            Details : In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.

                            Product Name : MEDI4736

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            August 17, 2020

                            Lead Product(s) : Durvalumab,Trametinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cedazuridine,Decitabine,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Astex Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Astex Pharmaceuticals and MD Anderson Collaborate to Accelerate Clinical Evaluation of Therapies for Patients ...

                            Details : The initial focus will be on evaluating Astex’s oral decitabine and cedazuridine hypomethylating agent (INQOVI®) in combinations with other therapies. MD Anderson and Astex will design new clinical studies to be conducted at MD Anderson.

                            Product Name : Inqovi

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            August 09, 2020

                            Lead Product(s) : Cedazuridine,Decitabine,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Astex Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WNT974,Spartalizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I Clinical Trial Shows WNT974 In Combination With Spartalizumab Well Tolerated for Advanced Solid Tumor ...

                            Details : WNT974 is an oral inhibitor of Porcupine, an acyltransferase that plays a key role in Wnt ligand secretion and activity. Wnt signaling pathways are a group of signal transduction pathways, which begin with proteins that pass signals into a cell through c...

                            Product Name : WNT974

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 27, 2020

                            Lead Product(s) : WNT974,Spartalizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            The University of Texas MD Anderson Cancer Center

                            U.S.A arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : WP1122

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Moleculin Biotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses

                            Details : Moleculin will supply the lead drug candidate, WP1122, and related inhibitors, also technical support for UTMB to begin testing these candidates against viral disease models, including COVID-19.

                            Product Name : WP1122

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 17, 2020

                            Lead Product(s) : WP1122

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Moleculin Biotech

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth